• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Maxipime (cefepime hydrochloride) powder for injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- September 2009


Summary View



Information for Patients
  • Patients should be advised of neurological adverse events that could occur with Maxipime use. Patients should be instructed to inform their healthcare provider at once of any neurological signs and symptoms including encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus and seizures for immediate treatment, dosage adjustment, or discontinuation of Maxipime.